Harvard Bioscience(US:HBIO)2025-05-12 11:18Financial Performance - Revenue for Q1 2025 was $21.8 million, a decrease compared to $24.5 million in Q1 2024[6] - Gross margin for Q1 2025 was $12.2 million, representing 56.0% of revenue, compared to $14.8 million or 60.3% of revenue in Q1 2024[6] - The company reported an operating loss of $49.7 million in Q1 2025, which includes a goodwill impairment of $48.0 million, compared to an operating loss of $2.3 million in Q1 2024[6] - Adjusted EBITDA for Q1 2025 was $0.8 million, or 3.7% of revenue, compared to $1.6 million or 6.6% of revenue in Q1 2024[6] Product Revenue by Region - In the Americas, CMT product revenue for Q1 2025 was $9.58 million, while Pre-Clinical revenue was $12.32 million[7] - Total revenue in Q1 2025 was $21.77 million, including a negative currency adjustment of $0.13 million[7] Outlook - The company expects Q2 revenues to range from $18 million to $20 million[17] - The company expects Q2 gross margin to range from 55% to 57%[17] Strategic Initiatives - The company is focused on expanding the adoption of new products while managing costs, with cost reduction actions expected to result in operating cost reductions of approximately $1 million per quarter beginning in Q2[16]